ClinicalTrials.Veeva

Menu

Prediction Model for the Risk of Developing Foot Ulcers in Diabetes

S

Sahlgrenska University Hospital

Status

Enrolling

Conditions

Diabete Mellitus

Study type

Observational

Funder types

Other

Identifiers

NCT07307183
Dnr 2025-03432-01

Details and patient eligibility

About

Introduction Foot ulcers in diabetes mellitus (DM) are a common and serious complication that can lead to infection, amputation, and increased mortality. Early identification of patients at high risk is crucial in order to implement preventive measures at an early stage. The number of people with DM is increasing globally, from 540 million in 2021 to an estimated 780 million by 2045. Foot ulcers cause considerable suffering for the individual and entail substantial costs for the healthcare system.

Despite national guidelines recommending regular, structured foot examinations and risk classification to assess the risk of developing foot ulcers, current risk models do not take into account the complex interactions between risk factors and socioeconomic factors such as marital status, level of education, and place of residence.

Data-driven advances and artificial intelligence (AI) offer new opportunities to refine risk identification, but their use in predicting the risk of diabetic foot ulcers remains limited. The need for foot screening is considerable. In Sweden, there are approximately 600,000 patients with DM, and half of them live with an increased risk due to nerve damage in the feet. This means that, based on risk level, around 300,000 patients in Sweden may require preventive interventions, including medical foot care, customised footwear, and access to specialist care for those with foot ulcers. Improved preventive efforts are emphasised in the person-centred and integrated care pathway for people with diabetes at high risk of foot ulcers. However, accurate identification of foot ulcer risk is currently lacking.

Prevention leads not only to good quality of life for the individual but also to reduced healthcare costs. Estimates by Ragnarsson Tennvall show that a hard-to-heal ulcer costs approximately SEK 100,000 per year, while an amputation costs around SEK 300,000-500,000. Given a prevalence of foot ulcers of 5% among patients with diabetes, the annual cost of ulcer care amounts to SEK 3 billion. In addition, there are costs of approximately SEK 750 million for amputations, according to data from the quality register SwedAmp.

The aim of the study is to develop, test, and validate prediction models (statistical and AI-based) to identify patients with DM who are at risk of developing foot ulcers. The models will be based on retrospective electronic health record data from primary care in the Västra Götaland Region (VGR), as well as data from Statistics Sweden (SCB) concerning demographic factors such as marital status, level of education, occupation, and place of residence.

Methods The study has two methodological approaches: AI-based modelling and statistical modelling.

AI-based approach Machine learning models will be developed to predict patients at risk of developing diabetic foot ulcers. The models will be trained using cross-validation on a large dataset in which variables will be iteratively excluded. Conformal prediction will be used to quantify uncertainty in patient-level predictions. The resulting models will be analysed to identify the strongest predictors and will be compared with classical statistical modelling and findings from the literature.

Steps in AI modelling:

Data extraction: Electronic health record data from primary care in VGR, supplemented with sociodemographic data from SCB.

Data processing: Use of, among other variables, diagnostic codes (ICD-10), healthcare interventions (KVÅ codes), visit types, visit frequency, ECG parameters, and free-text data to construct predictors.

Model development: Prediction models will be developed and trained using cross-validation. Measures of uncertainty will be generated using conformal prediction.

Validation: A separate cohort will be used to test model performance (sensitivity, specificity, positive predictive value [PPV]).

Interpretation: The models will be reviewed for transparency and clinical interpretability in collaboration with patient representatives, clinicians, and researchers.

The results of the statistical and AI-based models will be compared with regard to their respective strengths and weaknesses.

Statistical modelling Two populations will be analysed: patients with diabetes without foot ulcers and patients with diabetes with foot ulcers. Co-variation and causal relationships between risk factors and foot ulcers will be identified. A model describing causal pathways leading to ulcer development will be developed, and its certainty and uncertainty will be analysed.

Full description

In this register-based study, using data from Närhälsan's electronic health record system in the Västra Götaland Region (VGR) and linkage with data from Statistics Sweden (SCB), the research questions will be addressed through the development and validation of AI-based models. At a later stage of the process, the ability of the AI models to predict foot ulcers will be compared with that of statistical models.

From Asynja Whisp, Närhälsan's electronic health record system in VGR, data will be retrieved for all adult patients (18 years or older) with diagnoses (according to ICD-10) who either have a diabetes diagnosis (E10-E14) or have been prescribed any diabetes medication after the age of 18, covering the period from 2014 to 30 June 2025.

Based on, among other variables, diagnostic codes (ICD-10), procedure codes (KVÅ), visit types, visit frequency, ECG parameters, and free-text/clinical notes, predictors will be identified, such as neuropathy, impaired circulation, previous ulcers, antibiotic treatment, foot deformities, and skin status. The data will be validated and, if necessary, supplemented with additional parameters.

Methods to address the research questions

Machine learning-based models will be trained to predict the risk of developing foot ulcers. Cross-validation will be used to identify optimal hyperparameters for each model. In the first phase, the models' ability to discriminate between patients with diabetic foot ulcers and patients without foot ulcers will be evaluated. In the second phase, the models' ability to prospectively predict ulcer development will be assessed. Redundant variables will be excluded, and the models will be retrained in an iterative process to increase robustness.

The models will be combined with conformal prediction to integrate uncertainty estimation into the predictions and to identify patients for whom the model is unsuitable for prediction. Finally, the most predictive variables will be identified using Shapley values (SHAP).

Statistical models

Using electronic health record data from the Asynja Whisp care information system in VGR primary care, together with SCB data and scientific and empirical evidence, variables and categories that constitute potential risk factors for foot ulcers will be identified. A case-control design will be applied, in which the control group consists of people with diabetes who have not developed foot ulcers, compared with patients who have developed foot ulcers.

In the development of statistical prediction models, the workflow involves analysing populations, i.e. all patients with diabetes without foot ulcers compared with all patients with diabetes who have foot ulcers. This allows investigation of potential associations between the occurrence of foot ulcers in patients with diabetes and other factors. In collaboration with the medical profession, causal relationships underlying the occurrence of foot ulcers will be identified. A model will be developed that describes chains of causation leading to the occurrence of foot ulcers in patients with diabetes, and information will be provided on the degree of certainty of the model.

Based on the results of the models (both AI-generated and statistical), strengths and weaknesses of each approach will be compared. Validation of the developed models will be performed on an independent dataset to ensure that the results are generalisable and robust over time.

The validation strategy ensures that the model performs well on new patients and not only on the dataset from which it was developed. Outcome measures for validation include sensitivity (how well the model identifies those who truly have a high risk of foot ulcers), specificity (how well the model avoids false alarms), and positive predictive value (PPV). Furthermore, the model will be interpreted to ensure transparency and clinical interpretability. Development, testing, and validation will be conducted in collaboration with patient representatives, clinicians, and researchers.

Enrollment

100,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients aged 18 years or older at the time of inclusion
  • Patients with a diagnosis of diabetes mellitus according to ICD-10 codes E10-E14, and/or
  • Patients who have been prescribed at least one diabetes-related medication after the age of 18
  • Patients with relevant diagnoses and/or prescriptions recorded in the study data sources between 1 January 2014 and 30 June 2025

Exclusion criteria

  • Patients younger than 18 years of age at the time of diabetes diagnosis or prescription
  • Patients with no recorded diagnosis of diabetes (ICD-10 E10-E14) and no prescription of diabetes medication after the age of 18
  • Patients with incomplete or missing key data required for model development or validation (e.g. missing outcome or essential covariates)

Trial design

100,000 participants in 2 patient groups

Patients with diabetes with foot ulcers
Description:
Patients with diabetes and foot ulcers registered in the electrical medical record system from primary care in Region Västragötaland.
Patients with diabetes without foot ulcers
Description:
Patients with diabetes without foot ulcers registered in the electrical medical record system from primary care in Region Västragötaland.

Trial contacts and locations

1

Loading...

Central trial contact

Thomas Fasth, BSc; Ulla Hellstrand Tang, Associate Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems